https://scholars.lib.ntu.edu.tw/handle/123456789/626867
標題: | Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study | 作者: | CHIA-HSUIN CHANG YI-CHENG CHANG JOU-WEI LIN Chen, Shu-Ting LEE-MING CHUANG Lai, Mei-Shu |
關鍵字: | ACTIVATED PROTEIN-KINASE; IMPAIRED GLUCOSE-TOLERANCE; HEART-FAILURE; MYOCARDIAL-INFARCTION; BODY-COMPOSITION; DISEASE; MORTALITY; SULFONYLUREAS; OUTCOMES; THERAPY | 公開日期: | 三月-2015 | 出版社: | ENDOCRINE SOC | 卷: | 100 | 期: | 3 | 起(迄)頁: | 1121 | 來源出版物: | The Journal of clinical endocrinology and metabolism | 摘要: | Metformin is the first-line oral therapy for type 2 diabetes with proven benefits against cardiovascular risk. Recent evidence suggested that acarbose might be similar to metformin in glucose-lowering efficacy and cardiovascular risk reduction. Therefore, international guidelines have suggested the use of acarbose as alternative first-line antidiabetic therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/626867 | ISSN: | 0021-972X | DOI: | 10.1210/jc.2014-2443 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。